The University of Manchester is part of the prestigious Russell Group of universities, with outstanding facilities and the widest range of courses. We are highly respected across the globe as a center of teaching excellence and innovative research.
With 25 Nobel prize winners among our current and former staff and students, we have a history of world firsts and brilliant discoveries, from splitting the atom to giving the world graphene.
We’re committed to world-class research, an outstanding learning and student experience, and social responsibility in everything we do.
In the project, the University of Manchester team will design and deliver Pilot 1, Study of Genomics and Epigenomics Markers for Early Risk Assessment of Pancreatic Cancer. The pilot aims to (i) provide individuals with information about their personalised risk factors for future disease to raise awareness of health conditions and educate individuals on how to prevent life threatening diseases like Pancreatic Cancer. The team will also support the efforts aiming at personalisation of user interfaces, communication, and feedback mechanisms used in iHelp. Such personalisation approaches can facilitate acceptance of iHelp and its continuous use. This in turn can translate into greater awareness and adherence to healthy behaviours, which can impact the individual quality of life and increase life span.